학술논문

CONSIGN - an open-label phase-3B-study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy
Document Type
Journal
Source
ONCOLOGY RESEARCH AND TREATMENT; 2016, 39 p10-p10, 1p. Supplement: 1
Subject
Language
English
ISSN
22965262